The U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, awarded a $95,972,719.78 definitive, cost-no-fee contract to Pfizer Inc. to provide innovative treatments for multidrug resistant infections. The contract, which does not have a set-aside designation, runs through September 30, 2025. Pfizer, a major pharmaceutical manufacturer, will deliver a range of medical products and services directly to facilities in the United Kingdom to support federal health programs and initiatives. This contract award is part of Pfizer's broader portfolio of federal contracts, including a $1.9 billion Vaccines for Children indefinite-delivery/indefinite-quantity (ID/IQ) contract with the Centers for Disease Control and Prevention, and a $1.3 million blanket purchase agreement with the Department of Veterans Affairs to supply a treatment for sickle cell disease.
Generated 6/14/24, 9:35 AM